Is the active ingredient.
Type 2 diabetes mellitus (in combination with diet and exercise, often as a secondline treatment after metformin failure)
Improvement of glycemic control in adults with type 2 diabetes
Ogli 15mg Tablet (Pioglitazone) is a thiazolidinedione (TZD) that improves insulin sensitivity by binding to peroxisome proliferator-activated receptor gamma (PPAR-γ). This action increases the body's responsiveness to insulin, leading to improved glucose uptake by cells and reduced blood glucose levels. It also may have beneficial effects on lipid metabolism.
Store at room temperature (20°C-25°C), protect from moisture and light. Keep out of reach of children.
Dosage should be determined by your doctor based on your individual needs and response to treatment.
Typically started at a low dose and gradually increased as tolerated.
Always follow your doctor's prescribed dosage and administration instructions.
Heart failure (worsening of existing condition or new onset)
Fluid retention (edema)
Weight gain
Bone fractures
Liver problems (rare but serious)
Headache
Nausea
Upper respiratory infections
Alcohol consumption should be discussed with your doctor, as it can affect blood glucose control.
Pioglitazone may cause dizziness or lightheadedness in some individuals, so caution is advised when driving or operating machinery, especially when starting treatment or increasing dosage.
Not recommended during pregnancy or breastfeeding. Discuss with your doctor immediately if pregnancy occurs.
Not indicated for use in children.
Dosage adjustment may be needed in patients with moderate to severe kidney disease.
Regular liver function tests are recommended, especially during the initial phase of treatment, to monitor for liver damage.
Consult your doctor or pharmacist for detailed product information. Always refer to the official drug monograph for the most current and comprehensive information.
